Table 3.
Univariate and multivariate logistic regression analysis of overall survival
| Parameter | Univariate | Multivariate | ||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Sex (men vs. women) | 1.02 (0.61–1.72) | 0.912 | ||
| Age (< 70 vs. ≥ 70 years) | 1.19 (0.72–1.95) | 0.488 | ||
| Preoperative CA19-9 (< 338.45 vs. ≥ 338.45) | 1.04 (0.60–1.80) | 0.871 | ||
| Tissue size (3, 4 vs. 1, 2) | 1.12 (0.56–2.22) | 0.754 | ||
| ly (positive vs. negative) | 3.50 (1.09–11.2) | 0.035a | 2.27 (0.56–9.09) | 0.246 |
| v (positive vs. negative) | 1.36 (0.96–1.93) | 0.082 | ||
| Pathological T factor (≥ 3 vs. < 3) | 1.09 (0.15–7.95) | 0.928 | ||
| Lymph node metastasis (positive vs. negative) | 2.69 (1.07–6.75) | 0.034a | 2.03 (0.74–5.52) | 0.164 |
| Residual tumor (≥ 1 vs. 0) | 1.94 (0.94–4.01) | 0.073 | ||
| Time to start AC (≥ 42 vs. < 42 days) | 1.21 (0.65–2.22) | 0.527 | ||
| TDI (< 62.5% vs. ≥ 62.562.5) | 3.10 (1.86–5.15) | < 0.001a | 3.38 (2.01–5.70) | < 0.001a |
HR Hazard ratio, ly Lymphatic permeation, v Blood vessel invasion, AC Adjuvant chemotherapy, TDI Total dose intensity
aStatistically significant